Continuous Inotrope Therapy in Hospice Care: A Case Series.
Citation: American Journal of Hospice & Palliative Medicine. 36(7):660-663, 2019 Jul.PMID: 30630349Institution: MedStar Washington Hospital CenterDepartment: Medicine/Palliative Care | PharmacyForm of publication: Journal ArticleMedline article type(s): Journal ArticleSubject headings: *Cardiotonic Agents/tu [Therapeutic Use] | *Heart Failure/dt [Drug Therapy] | *Heart Failure/nu [Nursing] | *Hospice Care/mt [Methods] | Aged | Aged, 80 and over | Female | Humans | Male | Middle Aged | Retrospective StudiesYear: 2019Local holdings: Available online from MWHC library: 1999 - present, Available in print through MWHC library:1999-2007ISSN:- 1049-9091
- Groninger, Hunter:
- https://orcid.org/0000-0001-7416-1999
Item type | Current library | Collection | Call number | Status | Date due | Barcode |
---|---|---|---|---|---|---|
Journal Article | MedStar Authors Catalog | Article | 30630349 | Available | 30630349 |
Available online from MWHC library: 1999 - present, Available in print through MWHC library:1999-2007
BACKGROUND:: Continuous cardiac inotropes are increasingly utilized for symptom management in advanced heart failure (AHF). Among patients who are not eligible for cardiac transplant or mechanical circulatory support, many are hospice eligible at the time of inotrope initiation. Nevertheless, given relative infrequent use as well as cost issues, acceptability and management of inotropes in the hospice setting are likely widely variable between hospice agencies.
CONCLUSION:: Cardiac inotropes can align with both the goals of care for the patient with AHF and the philosophy of hospice care. Patients with AHF admitted to hospice care on continuous inotropes may live days to weeks, whether or not inotropes are discontinued.
DESIGN:: Single-institution retrospective chart review of patients with AHF receiving continuous inotropes who were discharged from the hospital to hospice care between February 2015 and October 2016 and survey of hospice medical directors providing direct care of these patients.
OBJECTIVE:: To describe hospice care experiences for patients with AHF receiving continuous inotrope therapies and weaning inotropes at the end of life.
RESULTS:: Eighteen patients with AHF receiving continuous inotropes were discharged to 6 hospice agencies. Twelve patients were weaned from inotropes prior to death. Among cases where the inotrope was weaned, patients lived several days to more than 2 weeks. All hospice medical directors surveyed would accept patients on inotropes again. Most believed that providing continuous inotrope therapy for patients with AHF is compatible with the philosophy of hospice care.
English